A Phase 1 interventional study of ARN-75039 oral capsules and Placebo in Healthy Adult Participants, sponsored by Arisan Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Arisan Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need. ARN-75039-101 study was a randomized, double-blind, placebo-controlled study that assessed the safety, tolerability, and PK of escalating single and multiple doses of ARN 75039 when administered by the oral route in healthy adult subjects in six single ascending dose (SAD - Part 1) cohorts and five multiple ascending dose (MAD - Part 2) cohorts.
In Part 1 (SAD), eight subjects per cohort (except for 10 subjects in cohort 3, evaluating the effects of food) were enrolled to receive the study drug orally in the fed state. Within each cohort of eight subjects, the first two subjects (Sentinel) were randomly assigned in a 1:1 ratio to receive a single dose of ARN-75039 capsules or placebo (microcrystalline cellulose). After the medical monitor reviewed the first 3 days of blinded safety for these subjects, an additional 6 subjects (the remaining cohort) were randomly assigned in a 5:1 (active: placebo) ratio. Within the food-effect cohort of 10 subjects, the first two subjects (Sentinel) were randomly assigned in a 1:1 ratio to receive ARN-75039 capsules or a placebo in the fasted state. After the medical monitor reviewed the first three days of blinded safety for these subjects, an additional 8 subjects (the rest of the cohort) were randomly assigned in a 7:1 (active: placebo) ratio.
The Part 2 (MAD) dosing plan consisted of two days of lead-in doses followed by eight days of maintenance dosing. All doses were administered twice daily (BID), approximately 10 hours apart:
The study was conducted in three study periods (Screening Period, Treatment Period, and Follow-up Period). During the Treatment Period, safety was assessed at each study visit, and PK assessments were conducted at specific time points per the assessment schedule. Subjects who received at least one dose of the study drug were instructed and encouraged to complete all study visits. Subjects in the Treatment period had spans of residency at the study site as well as ambulatory periods in each part of the study. Subjects returned to the study site for follow-up evaluations according to the Schedule of Assessments (SOA) during the Treatment Period. After completing the Treatment Period, subjects entered the Safety Follow-up Period, consisting of 14 days for the SAD part of the study and 28 days for the MAD part, culminating in an End-of-study (EOS) visit. For subjects who withdrew from the study prematurely, the EOS visit was conducted within seven days after the last study drug dose.
Arisan Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Currently enrolled in another device or drug study, or less than 30 days or 5 half-lives of the prior investigational agent (whichever is longer) or plans to enroll in another investigational device or drug study during the course of this study.
Part 2 (MAD) only:
History of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating single or multiple doses of ARN-75039 oral capsules
Drug: ARN-75039 oral capsules
Specified weight of placebo (microcrystalline cellulose) corresponding to the dose of ARN-75039 within the same cohort and encapsulating it in a HPMC capsule prior to dosing.
Drug: Placebo
active oral study drug prepared and administered as oral capsules
Also known as: ARN75039
Given at frequency and amounts matching ARN- 75039 dosing regimen
Also known as: Matching placebo oral capsules (Cohorts 1 through 11)
Incidence of Treatment-Emergent Adverse Events (TEAEs)
A treatment-emergent adverse event (TEAE) was defined as any adverse event that began or worsened after administration of the study drug (ARN-75039 or placebo) through the End-of-Study visit.
Time frame: From first dose through the End-of-Study (EOS) visit: Part 1 (SAD), through Day 15/EOS; Food-effect cohort, through the second treatment period and Day 29/EOS; Part 2 (MAD), from Day 1 through Day 39/EOS.
Incidence of Treatment-Emergent Serious Adverse Events (TESAEs)
Number of participants with at least one treatment-emergent Serious adverse event (TESAE). A TESAE is any adverse event that starts or worsens after administration of study drug (ARN-75039 or placebo).
Time frame: From first dose through the End-of-Study (EOS) visit: Part 1 (SAD), through Day 15/EOS; Food-effect cohort, through the second treatment period and Day 29/EOS; Part 2 (MAD), from Day 1 through Day 39/EOS.
Part 1-SAD: Cmax
Maximum Observed Plasma Concentrations of ARN-75039 (Cmax); Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.
Time frame: Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.
Part 1-SAD: Tmax
PK of ARN-75039 in healthy subjects as assessed by time to reach Cmax (Tmax) towards the determination of the optimal PK dose
Time frame: Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.
Part 1-SAD: Terminal Half-life
PK of ARN-75039 in healthy subjects as assessed by terminal elimination half-life (T1/2)
Time frame: Derived from plasma samples collected from Day 1 predose through 336 hours (Day 15/EOS) postdose.
Part 1-SAD: AUC
PK of ARN-75039 in healthy subjects as assessed by plasma exposure (AUC), determination of the optimal PK dose
Time frame: Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.
Part 2-MAD: Cmax0-10h
Maximum Plasma Concentrations of ARN-75039 at 1 and 10 days. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen
Time frame: Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.
Part 2-MAD: Tmax0-10h.
Time to maximum ARN-75039 concentration. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.
Time frame: Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.
Part 2-MAD: AUC0-10h
Area Under the Concentration Time Profile. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.
Time frame: Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.
This study was conducted at a single site in the United States from January 23, 2023 (first participant visit) to March 28, 2025 (last participant visit). The study included Screening, Treatment, and Follow-up periods.
| Milestone | Part 1- SAD: Cohort 1 (30mg, Fed) | Part 1- SAD: Cohort 2 (100mg, Fed) | Part 1- SAD: Cohort 3 (300mg, Fed and Fasted for FE) | Part 1- SAD: Cohort 4 (600mg, Fed) | Part 1- SAD: Cohort 5 (1200mg, Fed) | Part 1- SAD: Cohort 6 (2000mg, Fed) | Part 1- SAD: Placebo (Fed and Fasted) | Part 2- MAD: Cohort 7 (Fed) | Part 2- MAD: Cohort 8 (Fed) | Part 2- MAD: Cohort 9 (Fed) | Part 2- MAD: Cohort 10 (Fed) | Part 2- MAD: Cohort 11 (Fed) | Part 2- MAD: Placebo (Fed) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 8 | 6 | 6 | 6 | 12 | 6 | 6 | 6 | 7 | 7 | 12 |
| Completed | 6 | 6 | 8 | 6 | 6 | 5 | 11 | 6 | 6 | 5 | 6 | 6 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Maximum Observed Plasma Concentrations of ARN-75039 (Cmax); Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.
| ng/mL | Cohort 1 (30mg, Fed) | Cohort 2 (100mg, Fed) | Cohort 3 (300mg, Fed) | Cohort 3 (300mg, Fasted) | Cohort 4 (600mg, Fed) | Cohort 5 (1200mg, Fed) | Cohort 6 (2000mg, Fed) |
|---|---|---|---|---|---|---|---|
| Part 1-SAD: Cmax | 141.3 ± 48.359 | 442.0 ± 134.76 | 1281 ± 445.04 | 722.1 ± 281.30 | 1962 ± 762.01 | 2687 ± 1252.2 | 2933 ± 554.24 |
PK of ARN-75039 in healthy subjects as assessed by time to reach Cmax (Tmax) towards the determination of the optimal PK dose
| h | Cohort 1 (30mg, Fed) | Cohort 2 (100mg, Fed) | Cohort 3 (300mg, Fed) | Cohort 3 (300mg, Fasted) | Cohort 4 (600mg, Fed) | Cohort 5 (1200mg, Fed) | Cohort 6 (2000mg, Fed) |
|---|---|---|---|---|---|---|---|
| Part 1-SAD: Tmax | 5.67 ± 0.81 | 6.03 ± 0.07 | 5.51 ± 0.93 | 4.27 ± 1.65 | 6.01 ± 3.33 | 5.67 ± 0.82 | 6.67 ± 2.74 |
A treatment-emergent adverse event (TEAE) was defined as any adverse event that began or worsened after administration of the study drug (ARN-75039 or placebo) through the End-of-Study visit.
| Participants | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fasted) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed) | Part 1-SAD: Placebo (Fasted) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (TEAEs) | 1 | 2 | 5 | 0 | 2 | 2 | 4 | 4 | 0 | 2 | 2 | 4 | 6 | 5 | 5 |
Number of participants with at least one treatment-emergent Serious adverse event (TESAE). A TESAE is any adverse event that starts or worsens after administration of study drug (ARN-75039 or placebo).
| Participants | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fasted) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed) | Part 1-SAD: Placebo (Fasted) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 | Part 2-MAD: Cohort 11 | Part 2-MAD: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence of Treatment-Emergent Serious Adverse Events (TESAEs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PK of ARN-75039 in healthy subjects as assessed by terminal elimination half-life (T1/2)
| h | Cohort 1 (30mg, Fed) | Cohort 2 (100mg, Fed) | Cohort 3 (300mg, Fed) | Cohort 3 (300 mg, Fasted) | Cohort 4 (600 mg, Fed) | Cohort 5 (1200 mg, Fed) | Cohort 6 (2000mg, Fed) |
|---|---|---|---|---|---|---|---|
| Part 1-SAD: Terminal Half-life | 4.27 ± 0 | 6.24 ± 1.97 | 15.43 ± 10.45 | 10.13 ± 9.66 | 137.3 ± 62.67 | 98 ± 39.82 | 90.34 ± 46.94 |
PK of ARN-75039 in healthy subjects as assessed by plasma exposure (AUC), determination of the optimal PK dose
| h*ng/mL | Cohort 1 (30mg, Fed) | Cohort 2 (100mg, Fed) | Cohort 3 (300mg, Fed) | Cohort 3 (300mg, Fasted) | Cohort 4 (600mg, Fed) | Cohort 5 (1200mg, Fed) | Cohort 6 (2000mg, Fed) |
|---|---|---|---|---|---|---|---|
| AUC 0-t | 952.3 ± 313.61 | 4184 ± 1276.9 | 15170 ± 4816.3 | 7593 ± 3833.8 | 32710 ± 6233.1 | 43650 ± 22149 | 56780 ± 14333 |
| AUC 0-∞ | 1448 ± 0 | 5004 ± 1266.7 | 15830 ± 4982.7 | 8083 ± 4132.0 | 38740 ± 8194.1 | 48860 ± 23704 | 62860 ± 16776 |
Maximum Plasma Concentrations of ARN-75039 at 1 and 10 days. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen
| ng/mL | Cohort 7 (Fed) | Cohort 8 (Fed) | Cohort 9 (Fed) | Cohort 10 (Fed) | Cohort 11 (Fed) |
|---|---|---|---|---|---|
| Cmax (day 1) | 144.7 ± 34.82 | 304.8 ± 45.86 | 678.8 ± 296.86 | 723.7 ± 139.6 | 1639 ± 615.63 |
| Cmax (day 10) | 76.42 ± 16.94 | 159.5 ± 27.60 | 346.3 ± 129.40 | 333.0 ± 73.54 | 800.0 ± 270.33 |
Time to maximum ARN-75039 concentration. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.
| h | Cohort 7 (Fed) | Cohort 8 (Fed) | Cohort 9 (Fed) | Cohort 10 (Fed) | Cohort 11 (Fed) |
|---|---|---|---|---|---|
| Tmax0-10h (day 1) | 4.7 ± 1.64 | 3.67 ± 1.51 | 3.20 ± 1.10 | 4.30 ± 0.75 | 4.00 ± 0.00 |
| Tmax0-10h (day 10) | 5.01 ± 1.10 | 5.35 ± 1.04 | 5.01 ± 1.16 | 4.67 ± 1.04 | 5.01 ± 1.10 |
Area Under the Concentration Time Profile. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.
| h*ng/mL | Cohort 7 (Fed) | Cohort 8 (Fed) | Cohort 9 (Fed) | Cohort 10 (Fed) | Cohort 11 (Fed) |
|---|---|---|---|---|---|
| AUC0-10h (day 1) | 821.8 ± 145.64 | 1651 ± 228.57 | 3805 ± 1439.5 | 4042 ± 876.96 | 9039 ± 2833.5 |
| AUC0-10h (day 10) | 548.7 ± 78.321 | 1197 ± 183.86 | 2322 ± 815.21 | 2433 ± 461.71 | 6270 ± 2264.2 |
Collected over From first dose through the End-of-Study visit: Part 1 (SAD), through Day 15/EOS (14 days after dosing); Food-effect cohort, through Day 29/EOS; Part 2 (MAD), through Day 39/EOS (28 days after the last dose on Day 10).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1-SAD: Cohort 1 (30mg, Fed) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1-SAD: Cohort 2 (100mg, Fed) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1-SAD: Cohort 3 (300mg, Fed) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Part 1-SAD: Cohort 3 (300mg, Fasted) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Part 1-SAD: Cohort 4 (600mg, Fed) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1-SAD: Cohort 5 (1200mg, Fed) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1-SAD: Cohort 6 (2000mg, Fed) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 1-SAD: Placebo (Fed) | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Part 1-SAD: Placebo (Fasted) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part 2-MAD: Cohort 7 (Fed) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 2: MAD: Cohort 8 (Fed) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 2-MAD: Cohort 9 (Fed) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 2-MAD: Cohort 10 (Fed) | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Part 2-MAD: Cohort 11 (Fed) | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Part 2-MAD: Placebo (Fed) | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Event | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fasted) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed) | Part 1-SAD: Placebo (Fasted) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical device site reactionGeneral disorders | 0/6 | 0/6 | 1/8 | 0/8 | 1/6 | 0/6 | 0/6 | 0/12 | 0/1 | 0/6 | 1/6 | 3/6 | 5/7 | 3/7 | 3/12 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/8 | 0/8 | 0/6 | 0/6 | 3/6 | 0/12 | 0/1 | 0/6 | 1/6 | 0/6 | 0/7 | 0/7 | 0/12 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 0/8 | 0/8 | 0/6 | 0/6 | 2/6 | 0/12 | 0/1 | 0/6 | 0/6 | 0/6 | 1/7 | 0/7 | 0/12 |
| HeadacheNervous system disorders | 0/6 | 0/6 | 0/8 | 0/8 | 0/6 | 2/6 | 0/6 | 0/12 | 0/1 | 0/6 | 0/6 | 0/6 | 0/7 | 1/7 | 1/12 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 2/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/12 | 0/1 | 0/6 | 0/6 | 0/6 | 0/7 | 0/7 | 0/12 |
| Feeling hotGeneral disorders | 0/6 | 0/6 | 0/8 | 0/8 | 0/6 | 0/6 | 1/6 | 0/12 | 0/1 | 0/6 | 0/6 | 0/6 | 0/7 | 0/7 | 1/12 |
| Swelling faceGeneral disorders | 0/6 | 0/6 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/12 | 0/1 | 0/6 | 1/6 | 0/6 | 0/7 | 0/7 | 0/12 |
| Vessel puncture site bruiseGeneral disorders | 0/6 | 0/6 | 1/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/12 | 0/1 | 0/6 | 1/6 | 0/6 | 0/7 | 0/7 | 0/12 |
| Vessel puncture site painGeneral disorders | 0/6 | 1/6 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/12 | 0/1 | 0/6 | 0/6 | 0/6 | 0/7 | 0/7 | 0/12 |
| Abnormal faecesGastrointestinal disorders | 0/6 | 0/6 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/12 | 0/1 | 0/6 | 1/6 | 0/6 | 1/7 | 0/7 | 0/12 |
The Safety Population included all subjects who received at least one dose of study drug (ARN-75039 or placebo). Baseline characteristics were summarized separately for Part 1 (SAD) and Part 2 (MAD) Safety Populations. Overall pooled descriptive statistics across both study parts were not calculated in the CSR for continuous variables (Age, BMI, weight, and height); therefore, overall values are not presented.
| Age, Continuous(Years) | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed and Fasted for Food Effect) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 43.7 ± 10.98 | 33.2 ± 12.09 | 39.6 ± 8.63 | 45.5 ± 10.39 | 29.5 ± 6.83 | 30.0 ± 7.77 | 37.3 ± 10.09 | 42.5 ± 7.71 | 41.2 ± 5.64 | 41.5 ± 11.41 | 34.9 ± 7.38 | 36.4 ± 7.14 | 33.0 ± 8.83 | 37.3 ± 9.7 |
| Sex: Female, Male(Participants) | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed and Fasted for Food Effect) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 3 | 1 | 3 | 6 | 2 | 1 | 5 | 6 | 4 | 5 | 46 |
| Male | 3 | 3 | 4 | 3 | 5 | 3 | 6 | 4 | 5 | 1 | 1 | 3 | 7 | 48 |
| Race (NIH/OMB)(Participants) | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed and Fasted for Food Effect) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 2 | 3 | 3 | 2 | 6 | 3 | 4 | 3 | 4 | 2 | 6 | 42 |
| White | 4 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 2 | 2 | 2 | 3 | 3 | 43 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed and Fasted for Food Effect) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 2 | 1 | 3 | 12 |
| Not Hispanic or Latino | 5 | 6 | 8 | 5 | 6 | 6 | 10 | 4 | 6 | 6 | 5 | 6 | 9 | 82 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Body Mass Index (BMI)(Kg/m^2) | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed and Fasted for Food Effect) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 27.18 ± 2.93 | 26.23 ± 3.57 | 29.13 ± 3.88 | 27.47 ± 3.39 | 26.68 ± 1.62 | 25.10 ± 5.41 | 26.18 ± 3.258 | 26.27 ± 2.67 | 27.63 ± 1.81 | 26.75 ± 2.25 | 30.67 ± 2.29 | 27.49 ± 1.98 | 26.90 ± 3.02 | 27.2 ± 3.19 |
| Weight(kg) | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed and Fasted for Food Effect) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 75.77 ± 11.31 | 76.47 ± 20.44 | 82.50 ± 12.27 | 77.90 ± 6.66 | 82.43 ± 13.84 | 79.80 ± 19.90 | 78.15 ± 14.20 | 76.03 ± 11.61 | 85.07 ± 3.00 | 77.17 ± 4.53 | 86.69 ± 11.77 | 77.40 ± 12.672 | 79.35 ± 15.161 | 79.6 ± 12.82 |
| Height(cm) | Part 1-SAD: Cohort 1 (30mg, Fed) | Part 1-SAD: Cohort 2 (100mg, Fed) | Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect) | Part 1-SAD: Cohort 4 (600mg, Fed) | Part 1-SAD: Cohort 5 (1200mg, Fed) | Part 1-SAD: Cohort 6 (2000mg, Fed) | Part 1-SAD: Placebo (Fed and Fasted for Food Effect) | Part 2-MAD: Cohort 7 (Fed) | Part 2: MAD: Cohort 8 (Fed) | Part 2-MAD: Cohort 9 (Fed) | Part 2-MAD: Cohort 10 (Fed) | Part 2-MAD: Cohort 11 (Fed) | Part 2-MAD: Placebo (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 167.05 ± 13.24 | 169.42 ± 14.11 | 168.51 ± 9.73 | 168.95 ± 10.22 | 175.05 ± 10.73 | 177.93 ± 13.08 | 172.54 ± 13.05 | 169.78 ± 9.16 | 175.68 ± 6.90 | 170.02 ± 7.20 | 167.79 ± 8.24 | 167.40 ± 12.12 | 171.30 ± 13.04 | 170.89 ± 11.04 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2023 to primary completion in Mar 2025, 26 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ARN-75039
Arisan Therapeutics, Inc.